| DC49301 |
HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM |
HS-(CH2)3CO-L-Ala-D-Ala-L-Ala-NH-CH2-S-(CH2)5-CO-DM is a drug-linker (peptide-cleavable) conjugate for ADC. DM indicates the maytansinoid moiety. |
|
| DC49303 |
(Rac)-Lys-SMCC-DM1 |
(Rac)-Lys-SMCC-DM1 ((Rac)-Lys-Nε-MCC-DM1) is the racemate of Lys-SMCC-DM1. Lys-SMCC-DM1 is a linker-payload component that has the potential to inhibit tubulin polymerization. Lys-SMCC-DM1 is the active metabolite of T-DM1.
|
|
| DC49311 |
Methyl azetidine-3-carboxylate hydrochloride |
Methyl azetidine-3-carboxylate hydrochloride is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Methyl azetidine-3-carboxylate hydrochloride is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs< |
|
| DC49312 |
tans-4-Hydroxy-D-proline hydrochloride |
tans-4-Hydroxy-D-proline hydrochloride is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). tans-4-Hydroxy-D-proline hydrochloride is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PR |
|
| DC49313 |
cis-4-Hydroxy-L-proline hydrochloride |
cis-4-Hydroxy-L-proline hydrochloride is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). cis-4-Hydroxy-L-proline hydrochloride is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. |
|
| DC49314 |
cis-4-Hydroxy-D-proline hydrochloride |
cis-4-Hydroxy-D-proline hydrochloride is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). cis-4-Hydroxy-D-proline hydrochloride is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs. |
|
| DC49325 |
Ethyl azetidine-3-carboxylate hydrochloride |
Ethyl azetidine-3-carboxylate hydrochloride is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Ethyl azetidine-3-carboxylate hydrochloride is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[2] |
|
| DC49326 |
D-Proline, 4-hydroxy-, methyl ester hydrochloride |
D-Proline, 4-hydroxy-, methyl ester hydrochloride is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). D-Proline, 4-hydroxy-, methyl ester hydrochloride is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[2 |
|
| DC49327 |
H-cis-Hyp-OMe hydrochloride |
H-cis-Hyp-OMe hydrochloride is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). H-cis-Hyp-OMe hydrochloride is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PR |
|
| DC49328 |
H-Hyp-OMe hydrochloride |
H-Hyp-OMe hydrochloride is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). H-Hyp-OMe hydrochloride is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[1]< |
|
| DC49329 |
tans-4-Hydroxy-D-proline methyl ester hydrochloride |
tans-4-Hydroxy-D-proline methyl ester hydrochloride is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). tans-4-Hydroxy-D-proline methyl ester hydrochloride is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs. |
|
| DC49346 |
Bi-Mc-VC-PAB-MMAE |
Bi-Mc-VC-PAB-MMAE consists ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). Bi-Mc-VC-PAB-MMAE is a drug-linker conjugate for ADC. |
|
| DC49349 |
Mal-amido-PEG9-Val-Ala-PAB-SG3200 |
Mal-amido-PEG9-Val-Ala-PAB-SG3200 is a cleavable ADC linker conjugate used in the synthesis of antibody-drug conjugates (ADCs). |
|
| DC49372 |
1-N-Boc-3-hydroxyazetidine |
1-N-Boc-3-hydroxyazetidine is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). 1-N-Boc-3-hydroxyazetidine is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs |
|
| DC49385 |
1-Boc-azetidine-3-carboxylic acid |
1-Boc-azetidine-3-carboxylic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). 1-Boc-azetidine-3-carboxylic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[2] |
|
| DC49387 |
1-Boc-azetidine-3-yl-methanol |
1-Boc-azetidine-3-yl-methanol is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). 1-Boc-azetidine-3-yl-methanol is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[1] |
|
| DC49388 |
H-Glu-OtBu |
H-Glu-OtBu is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). H-Glu-OtBu is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs[2 |
|
| A125 |
Trastuzumab deruxtecan
Featured
|
Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, and a topoisomerase I inhibitor. Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer. |
|
| DC50134 |
SC209 |
SC209, an ADC cytotoxin extracted from patent WO2021247798, is used in synthesis of anti-EGFR antibody-drug conjugate ADC. |
|
| DC50212 |
CL2E-SN38 |
CL2E-SN-38, a highly releasable and structurally stable antibody-SN-38-conjugate, is a part of the antibody drug conjugate (ADC). SN-38, the active metabolite of Irinotecan from camptothecins, is an Topoisomerase I inhibitor. |
|
| DC50213 |
Aminooxy CatB-LXR |
Aminooxy CatB-LXR (compound 10) is a drug-linker conjugates for ADC. |
|
| DC50214 |
MC-Val-Cit-PAB-DX8951 |
MC-Val-Cit-PAB-DX8951 is a drug-linker conjugate for ADC. MC-Val-Cit-PAB-DX8951 is composed of a DNA topoisomerase I DX-8951 and a cathepsin cleavable ADC linker.
|
|
| DC50215 |
MP-PEG8-Val-Lys-Gly-7-MAD-MDCPT |
MP-PEG8-Val-Lys-Gly-7-MAD-MDCPT is a drug-linker conjugate for antibody-drug conjugate (ADC). MP-PEG8-Val-Lys-Gly-7-MAD-MDCPT has the potential for cancer and autoimmune disease research. |
|
| DC50216 |
CL2E-SN38 TFA |
CL2E-SN-38 TFA, a highly releasable and structurally stable antibody-SN-38-conjugate, is a part of the antibody drug conjugate (ADC). SN-38, the active metabolite of Irinotecan from camptothecins, is an Topoisomerase I inhibitor. |
|
| DC50025 |
Deruxtecan
Featured
|
Deruxtecan, a topoisomerase I inhibitor, is an exatecan derivative (DX-8951 derivative) with a cleavable pepetide linker and a maleimide group. The maleimide group in Deruxtecan can react with antibody to form antibody-drug conguates (ADC) such as Trastuzumab deruxtecan (DS-8201a), which is a HER2-targeting antibody–drug conjugate. |
|
| DC71115 |
SN38 NHS ester
Featured
|
SN38 NHS ester is the NHS ester derivative of SN38. SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis. SN38 NHS ester can be used for the synthesis of antibody-drug conjugates (ADCs). |
|
| DC71150 |
Aminobenzenesulfonic auristatin E |
Aminobenzenesulfonic auristatin E is a drug-linker conjugate for ADC with potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic. |
|
| DC71647 |
INX-SM-56 |
INX-SM-56 is an anti-VISTA antibody drug conjugate and can be used for targeted delivery of anti-inflammatory agents. VISTA: V-region Immunoglobulin-containing Suppressor of T cell Activation. |
|
| DC71664 |
Val-Cit-PAB-MMAF sodium
Featured
|
Val-Cit-PAB-MMAF sodium is a drug-linker conjugate for ADC. Val-Cit-PAB-MMAF sodium contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin polymerization inhibitor MMAF.
|
|
| DC71665 |
Val-Cit-PAB-MMAF
Featured
|
Val-Cit-PAB-MMAF is a drug-linker conjugate for ADC. Val-Cit-PAB-MMAF contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin polymerization inhibitor MMAF.
|
|
